Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Professor Ming-Shiang Wu, director of the Taiwan Clinical Trial Consortium, elaborates on the activities of the organization and its role to promote Taiwan’s clinical trial infrastructure and attract more international…
Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to…
Grace Yeh, president and founder of PharmaEngine, gives an update on the company’s recent growth and development of their second nanomedicine cancer treatment. Yeh goes on to explain the unique…
Researchers from Taiwan and the USA may have found a vaccine for the Middle East respiratory syndrome coronavirus (MERS-CoV) – a deadly emerging disease with a mortality rate of over…
Deputy Minister for Science and Technology on Taiwan Fong Chin Su gives his insights on innovation, cybersecurity, and the current state of one of the world’s most exciting biotech industries.…
Gou Jen Wang, the co-founder of Vida BioTechnology, and Bing Chen Gu, General Manager elaborate on how Vida BioTechnology provides added value to its customers by focusing on simplified use,…
Weichyun Wong, president of SCI Pharmtech, discusses the API manufacturer’s transition from a Swiss-owned affiliate to a Taiwanese company. He also talks technology and regulatory challenges, as well as what…
Eugene Huang, chairman, and Hua-Lin Wu, consultant of Blue Blood Biotech Corp., provide insightful information on BB-101, a protein proven to be efficient for wound healing, while sharing their vision…
Michael H.J. Lai, Founder of Body Organ Biomedical Corporation, discusses Ologen’s success as the first ever eye tissue repair product and highlights the importance of global exposure for Taiwan-based companies.…
Ken-Shwo Dai, president and CEO of Visgeneer, explains his biotech’s expertise in medtech, skincare, gene therapy and diagnostics, as well as his plans to take the company public. Can you…
Jassy Wang, CEO of MegaPro Biomedical, a nanomedicine development company specializing in developing nanoparticles and nanomicelles, discusses the evolving nanomedicine market in Taiwan and reveals the company’s plans for future…
Daniel Huang, CEO of Genomics Bioscience, Taiwan’s largest commercial genome sequencing company, and Chairman of Pharmigene, a global leader in the development and manufacturing of genetic tests, documents how he…
See our Cookie Privacy Policy Here